Tactogen is a public benefit company developing a next generation of mental wellness medicines. 

Our goal is to make transformative medicines that are safer, more effective, and more accessible.

Developing IP That Provides Unique Value to Patients

Tactogen is a mission-based and research-driven pharmatech company that uses machine learning and targeted assays to identify promising medicines and new treatments. We seek to understand and leverage the ability of novel small molecules to improve health in a variety of contexts, including anxiety, depression, and stress-related disorders.

June 1, 2026

Tactogen ADVANCES PATENT PORTFOLIO, PUBLISHES PRECLINICAL STUDY

The company continues to advance its patent portfolio, both domestically and ex-U.S., including an awarded Eurasian patent in May for specific benzofuran-based compositions. 

November 12, 2024

TACTOGEN PRESENTS, PUBLISHES DATA ON NEW COMPOUNDS

In October, Tactogen presented a poster on our patented new chemical entity at the annual meeting of the Society for Neuroscience.

November 28, 2023

TACTOGEN'S CEO MATTHEW BAGGOTT FEATURED ON HAMILTON MORRIS PODCAST

Hamilton Morris released his podcast interview with Matthew Baggott.